Modulatory effects of PLG and its peptidomimetics on haloperidol-induced catalepsy in rats

Peptides

Volumn 20, Issue 6, 1999, Pages 761-767

  Costain, Willard J ^a   Buckley, Adam T ^a   Evans, Margaret C ^b   Mishra, Ram K ^a   Johnson, Rodney L ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Catalepsy; Dopamine; Haloperidol; Parkinson's disease; Peptidomimetic; PLG; Schizophrenia

Indexed keywords

HALOPERIDOL; PROLYLLEUCYLDIETHYLGLYCINAMIDE; PROLYLLEUCYLGLYCINAMIDE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CATALEPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; MOLECULAR MIMICRY; MSH RELEASE-INHIBITING HORMONE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032768194     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(99)00060-1     Document Type: Article

References (57)

1. Ashby C.R. Jr, Wang R.Y. Pharmacological actions of the atypical antipsychotic drug clozapine a review . Synapse. 24:1996;349-394.
2. Barbeau A. Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man. Lancet. 2:1975;683-684.
3. Barbeau A., Roy M., Gonce M., Labreoque L. Newer therapeutic approaches in Parkinson's disease. Poirier L.J., Sourkes T.L., Bedard P.J. Advances in Neurology. 1978;433-437 Raven Press, New York.
4. Barker J.L., Harrison N.L., Mariani A.P. Benzodiazepine pharmacology of cultured mammalian CNS neurons. Life Sci. 39:1986;1959-1968.
5. Baures P.W., Ojala W.H., Gleason W.B., Mishra R.K., Johnson R.L. Design, synthesis, X-ray analysis, and dopamine receptor-modulating activity of mimics of the "C5" hydrogen-bonded conformation in the peptidomimetic 2-oxo-3-(R)-[2(S)-pyrrolidinylcarbonyl)amino]-1-pyrrolidineacetamide. J Med Chem. 3722:1994;3677-3683.
6. Bhargava H.N. Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats. Neuropharmacology. 234:1984;439-444.
7. 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase. Life Sci. 349:1984;873-879.
8. 2 (MIF) in neurological test and clinical use. Naunyn Schmiedebergs Arch Pharmacol. 298:1977;79-81.
9. 1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol. 38:1990;939-949.
10. Chiu P., Rajakumar G., Chiu S., Johnson R.L., Mishra R.K. Mesolimbic and striatal dopamine receptor supersensitivity prophylactic and several effects of L-prolyl-L-leucyl-glycinamide (PLG) . Peptides. 6:1985;179-183.
11. Chiu S., Mishra R.K. Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl glycinamide. Eur J Pharmacol. 53:1979;119-125.
12. Chiu S., Paulose C.S., Mishra R.K. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor binding. Peptides. 2:1981;105-111.
13. Chiu S., Paulose C.S., Mishra R.K. Neuroleptic drug-induced dopamine receptor supersensitivity antagonism by L-prolyl-L-leucyl-glycinamide . Science. 214:1981;1261-1262.
14. Ehrensing R.H. Lithium and M.R.I.H. in tardive dyskinesia. Lancet. 2:1974;1459-1460.
15. Ehrensing R.H., Kastin A.J., Larsons P.F., Bishop G.A. Melanocyte stimulating hormone release inhibiting factor I and tardive dyskinesia. Dis Nerv Syst. 38:1977;303-307.
16. Ehrensing R.H., Kastin A.J., Wurzlow G.F., Michell G.F., Mebane A.H. Improvement in major depression after low subcutaneous (s.c.) doses of MIF-1. J. Affect Disord. 31:1994;227-233.
17. Evans M.C., Venkatraman S., Ojala W.H., Gleason W.B., Pradhan A., Mishra R.K., Johnson R.L. Synthesis and biological activities of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring α,α-disubstituted amino acids. J Med Chem. 42:1999;1441-1447.
18. 2. J Med Chem. 36:1993;3481-3483.
19. Gong L., Kostrzewa R.M., Kalbfleisch J.H. MIF-1 fails to modify agonist-induced oral activity in neonatal 6-OHDA-treated rats. Peptides. 14:1993;1159-1164.
20. Hara C., Kastin A.J. Biphasic effects of MIF-1 and Tyr-MIF-1 on apomorphine-induced stereotypy in rats. Pharmacol Biochem Behav. 254:1986;757-761.
21. Hara C., Kastin A.J. Acute administration of MIF-1 or Tyr-MIF-1 inhibits haloperidol-induced catalepsy in rats. Pharmacol Biochem Behav. 246:1986;1785-1787.
22. Huidobro-Toro J.P., Scotti de Carolis A., Longo V.G. Actions of two hypothalamic factors (TRH, MIF) and of angiotensin II on behavioral effects of l-DOPA and 5-hydroxytryptophan in mice. Pharmacol Biochem Behav. 2:1974;105-109.
23. 2 modified at the leucyl residue. J Med Chem. 33:1990;1828-1832.
24. 2 analogues possessing cyclic amino acid residues at the C-terminal position. J Med Chem. 29:1986;2100-2104.
25. 2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, ADTN. J Med Chem. 29:1986;2104-2107.
26. Johnson R.L., Smissman E.E., Plotnikoff N.P. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide. J Med Chem. 212:1978;165-169.
27. Kahn R.S., Davis K.L. New developments in dopamine and schizophrenia. Bloom F.E., Kupfer D.J. Psychopharmacology The Fourth Generation of Progress . 1995;1193-1203 Raven Press, New York.
28. Kostrzewa R.M., Fukushima H., Harston C.T., Perry K.W., Fuller R.W., Kastin A.J. Striatal dopamine turnover and MIF-I. Brain Res Bull. 46:1979;799-802.
29. Kostrzewa R.M., Hardin J.C., Snell R.L., Kastin A.J., Coy D.H., Bymaster F. MIF-I and postsynaptic receptor sites for dopamine. Brain Res Bull. 45:1979;657-662.
30. Kostrzewa R.M., Kastin A.J. Tyr-MIF-1 attenuates development of tolerance to spiperone-induced catalepsy in rats. Brain Res Bull. 316:1993;707-712.
31. Kostrzewa R.M., Kastin A.J., Sobrain S.K. Potentiation of apomorphine action in rats by L-prolyl-L-leucyl-glycine amide. Pharmacol Biochem Behav. 9:1978;375-378.
32. Kostrzewa R.M., Spirtes M.A., Klara J.W., Christensen C.W., Kastin A.J., Joh T.H. Effects of L-prolyl-L-leucyl-glycine amide (MIF-I) on dopaminergic neurons. Pharmacol Biochem Behav. 5:(suppl 1):1976;125-127.
33. Kostrzewa R.M., White T.G., Zadina J.E., Kastin A.J. MIF-1 attenuates apomorphine stereotypies in adult rats after neonatal 6-hydroxydopamine. Eur J Pharmacol. 1631:1989;33-42.
34. 2 (PLG, MIF-1). Peptides. 192:1998;403-406.
35. 2 receptor by L-pro-L-leu-glycinamide (PLG) analogue 3(R)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide. Prog Neuropsychopharmacol Biol Psychiatry. 14:1990;821-827.
36. Nair R.M.G., Kastin A.J., Schally A.V. Isolation and structure of hypothalamic MSH release-inhibiting hormone. Biochem Biophys Res Commun. 436:1971;1376-1381.
37. Ott M.C., Mishra R.K., Johnson R.L. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide. Brain Res. 737:1996;287-291.
38. Pignatiello M.F., Olson G.A., Kastin A.J., Ehrensing R.H., McLean J.H., Olson R.D. MIF-1 is active in a chronic stress animal model of depression. Pharmacol Biochem Behav. 323:1989;737-742.
39. Plotnikoff N.P. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH) DOPA potentiation and biogenic amine studies . Prog Brain Res. 42:1975;11-23.
40. Plotnikoff N.P., Kastin A.J. Pharmacological studies with a tripeptide l-prolyl-l-leucyl-glycinamide. Arch Int Pharmacodyn Ther. 211:1974;211-224.
41. Plotnikoff N.P., Kastin A.J. Oxotremorine antagonism by prolyl-leucyl-glycine amide administered by different routes and with several anticholinergics. Pharmacol Biochem Behav. 2:1974;417-419.
42. Plotnikoff N.P., Kastin A.J. Neuropharmacological tests with α-melanocyte stimulating hormone. Life Sci. 1811:1976;1217-1222.
43. Plotnikoff N.P., Kastin A.J., Anderson M.S., Schally A.V. DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF). Life Sci. 1022:1971;1279-1283.
44. Plotnikoff N.P., Kastin A.J., Anderson M.S., Schally A.V. DOPA potentiation by MIF. Life Sci. 10:1971;1279-1283.
45. Plotnikoff N.P., Minard F.N., Kastin A.J. DOPA potentiation in ablated animals and brain levels of biogenic amines in intact animals after prolyl-leucylglycinamide. Neuroendocrinology. 145:1974;271-279.
46. Rajakumar G., Naas F., Johnson R.L., Chiu S., Yu K.L., Mishra R.K. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG). Peptides. 8:1987;855-861.
47. Reed G.W., Olson G.A., Olson R.D. The Tyr-MIF-1 family of peptides. Neurosci Biobehav Rev. 18:1994;519-525.
48. Rupniak N.M.J., Kilpatrick G., Hall M.D., Jennen P., Marsden C.D. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulperide, or clozapine in rats. Psychopharmacology. 84:1984;512-519.
49. 2 receptor ontogeny. Peptides. 101:1989;35-39.
50. Savelli J.E., Chugh A., Cheng C., Mishra R.K., Johnson R.L. Modulation of N-methyl-D-aspartate (NMDA) antagonist-induced darting behaviour by the peptidomimetic PAMTA. Brain Res. 682:1995;41-49.
51. 2 (PLG; MIF-1). Life Sci. 40:1987;2007-2010.
52. Smith J.R., Morgan M. The effects of prolyl-leucyl-glycine amide on drug-induced rotation in lesioned rats. Gen Pharmacol. 133:1982;203-207.
53. 2. J Med Chem. 36:1993;256-263.
54. 2 receptor evidence for modulation of agonist affinity states in bovine striatal membranes . J Neurochem. 50:1988;960-968.
55. 2. J Med Chem. 36:1993;2356-2361.
56. 2 receptor modulating effects . Bioorg Med Chem Lett. 8:1998;2885-2890.
57. 2. J Med Chem. 31:1988;1430-1436.